AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17145598
Drug: Paracetamol 1g
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol 1g four times daily for 14 days
Trial: 8719187
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg/kg bolus followed by 0.20 mg/kg‐1/min‐1 infusion)
Trial: 8719187
Drug: Midazolam (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (90 micrograms/kg 2 min before induction) followed by half-strength propofol (1 mg/kg bolus with 0.10 mg/kg‐1/min‐1 infusion)
Trial: 22728633
Drug: Lactobacillus salivarius
RxNorm normalized name: Lactobacillus Salivarius
DrugBank: Lactobacillus salivarius (DB16544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus salivarius (4x10^9 colony forming units/g daily for 12 weeks)
Trial: 19951274
Drug: Rivastigmine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (up to 9 mg/day)
Trial: 19036143
Drug: Neoadjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiotherapy with Paclitaxel (50 mg/m2) and Carboplatin (AUC = 2) followed by surgery
Trial: 12970783
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction chemotherapy regimen (TAD 2+7) with GM-CSF
Trial: 12970783
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction chemotherapy regimen (TAD 2+7) without GM-CSF
Trial: 2052056
Drug: Acetaminophen (4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (4000 mg per day)
Trial: 2052056
Drug: Ibuprofen (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (low dose, 1200 mg per day)
Trial: 2052056
Drug: Ibuprofen (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (high dose, 2400 mg per day)
Trial: 28556500
Drug: Anti-TNF-alpha therapy
RxNorm normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF-alpha therapy in Group I (n = 15)
Trial: 28556500
Drug: PSG parameters
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PSG parameters at third month of anti-TNF-alpha therapy in Group I
Trial: 23571259
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with Ologen implant
Trial: 20100913
Drug: Pamapimod (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamapimod (300 mg once daily for 10 days)
Trial: 17445309
Drug: One-day prophylactic
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-day prophylactic antibiotic
Trial: 17445309
Drug: Three-day prophylactic
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-day prophylactic antibiotic
Trial: 11048993
Drug: Basiliximab plus
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Basiliximab plus dual immunosuppressive therapy (cyclosporine modified [Neoral] and corticosteroids)
Trial: 11048993
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with dual immunosuppressive therapy (cyclosporine modified [Neoral] and corticosteroids)
Trial: 9066996
Drug: Daily cigarette
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily cigarette consumption (20 or more cigarettes per day)
Trial: 8389026
Drug: Subcutaneous sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous sumatriptan 4 mg
Trial: 30354996
Drug: Serum TMAO
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum TMAO levels (measured in μmol/L)
Trial: 30354996
Drug: Serum TMAO
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum TMAO levels (≥1.79 μmol/L)
Trial: 30354996
Drug: Serum TMAO
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum TMAO levels (≥3.19 μmol/L)
Trial: 30354996
Drug: Interaction between
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interaction between TMAO and folate levels (≥7.7 ng/mL versus <7.7 ng/mL)
Trial: 25031198
Drug: liraglutide +
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: liraglutide + metformin
Trial: 24088749
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + metformin
Trial: 22499010
Drug: Drug conservation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug conservation arm (440 subjects)
Trial: 18843900
Drug: Oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metronidazole 500 mg twice a day for seven days
Trial: 18843900
Drug: One vaginal
RxNorm normalized name: estrone Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One vaginal tablet containing freeze-dried Lactobacillus rhamnosus once a week at bedtime for two months starting one week after the last antibiotic administration
Trial: 12218528
Drug: Mivacurium (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium (0.1 mg/kg) immediately after loss of consciousness (Group A)
Trial: 10487666
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment at 6 IU/m2 body surface-day
Trial: 10487666
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment at 3 IU/m2 body surface-day
Trial: 8598656
Drug: Sequential pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential pneumatic compression devices during surgery and 2 days postoperatively (Group 1, n = 25)
Trial: 8598656
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin (5000 U q 12 hr) starting 1 hr before surgery and for 7 days postop (Group 2, n = 38)
Trial: 6276949
Drug: Peripheral intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral intravenous nutrition (PIVN) with chemotherapy (adriamycin, vincristine, VP-16-213, and cyclophosphamide)
Trial: 6276949
Drug: Peripheral intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral intravenous nutrition (PIVN) with chemotherapy
Trial: 30232094
Drug: Continuous glucose
RxNorm normalized name: sub-q infusion pump w/continuous glucose monitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous glucose monitoring (CGM) with a paper guideline to target glucose control (2.6-10 mmol/L)
Trial: 17636113
Drug: Acetaminophen (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (15 mg/kg 4 times a day)
Trial: 17636113
Drug: Naproxen (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (5 mg/kg 4 times a day)
Trial: 17636113
Drug: Acetaminophen and
RxNorm normalized name: Acetaminophen and Aspirin Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen and Naproxen
Trial: 10409478
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of sublingual 17beta-oestradiol (E(2))
Trial: 6835896
Drug: Intravenous meptazinol
RxNorm normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous meptazinol 100 mg
Trial: 26218077
Drug: 5-Azacytidine (5-AZA)
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5-Azacytidine (5-AZA) at a dose of 75 mg/m2 s.c. administered on a schedule of 5 days on/weekend off/2 days on (5/2/2)
Trial: 24342746
Drug: Hépar 1
RxNorm normalized name: Lotilaner (ema epar: veterinary)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hépar 1 group (1 L Hépar and 0.5 L natural low‐mineral water daily)
Trial: 24342746
Drug: Hépar 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hépar 0.5 group (0.5 L Hépar and 1 L natural low‐mineral water daily)
Trial: 24342746
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (1.5 L natural low‐mineral water daily)
Trial: 19013613
Drug: Contigen injection
RxNorm normalized name: TRICOPHYTON ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contigen injection
Trial: 20439193
Drug: WBRT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WBRT + temozolomide (75 mg/m2/day for 21 or 28 days)
Trial: 15607839
Drug: Morphine (MO)
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine (MO)
Trial: 8146996
Drug: iodine brine
RxNorm normalized name: brine shrimp extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iodine brine concentrate (2 x 100 ml, daily iodine uptake approximately 9 mg)
Trial: 31615318
Drug: Antibiotics +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics + anti-inflammatory + purified micronized flavonoid fraction (Group 2)
Trial: 31615318
Drug: Antibiotics +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics + anti-inflammatory + alpha-blocker (Group 1)
Trial: 21996130
Drug: Malleable protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malleable protein matrix (MPM) from whey in low-fat yoghurt (150 g, two servings daily for 3 months)
Trial: 21996130
Drug: Placebo yoghurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo yoghurt (matching control, identical in protein content 15 g/d)
Trial: 12895195
Drug: Cerivastatin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin (0.2 mg daily)
Trial: 10373050
Drug: C+E (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C+E (5 mg . kg(‐1) caffeine + 1 mg . kg(‐1) ephedrine)
Trial: 6407501
Drug: Fluvoxamine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (maximum 300 mg daily)
Trial: 6407501
Drug: Imipramine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (maximum 200 mg daily)
Trial: 24801219
Drug: CCRC (compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCRC (compound Congrongyizhi Capsule) treatment
Trial: 9688376
Drug: 0.5% ferric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ferric hyaluronate adhesion prevention gel
Trial: 9688376
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution (Control)
Trial: 2684659
Drug: Epidural anaesthesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural anaesthesia with morphine
Trial: 2684659
Drug: Epidural anaesthesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural anaesthesia without morphine
Trial: 23688146
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for childhood anxiety
Trial: 21855408
Drug: Evening bright
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening bright light exposure (∼4000 lux) for 45 minutes daily
Trial: 21855408
Drug: Morning bright
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning bright light exposure (∼4000 lux) for 45 minutes daily
Trial: 9169338
Drug: 6% crude
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% crude coal tar (CCT) ointment
Trial: 8228797
Drug: tPA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tPA (100 mg 3 h‐1)
Trial: 31703672
Drug: Estimation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estimation of compounded medications expiration date
Trial: 31703672
Drug: Commonly compounded
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commonly compounded dosage forms
Trial: 31703672
Drug: Preparation of
RxNorm normalized name: kit for the preparation of Ga-68
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation of sterile products
Trial: 19938710
Drug: Goal-oriented infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goal-oriented infusion therapy with monitoring of central hemodynamic parameters and passive leg raising test
Trial: 19938710
Drug: Standard infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard infusion therapy (a combination of colloids and crystalloids (1:1) at a rate of 6‐7 ml/kg/h)
Trial: 17466815
Drug: Sequential Multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Multiple Assignment Randomized Trial (SMART)
Trial: 15951872
Drug: Acute normovolemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute normovolemic hemodilution (ANH) - autologous blood 15 mL kg(‐1) withdrawn and replaced by 6% hydroxyethylstarch (HES)
Trial: 15951872
Drug: Acute hypervolemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute hypervolemic hemodilution (HHD) - HES administered without removal of any autologous blood
Trial: 12831588
Drug: Single-dose (SD)
RxNorm normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose (SD) protocol of cetrorelix (3 mg); n = 541
Trial: 12831588
Drug: Multiple-dose (MD)
RxNorm normalized name: miconazole nitrate Topical Solution [Nail MD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose (MD) protocol of cetrorelix (0.25 mg/day); n = 1066
Trial: 10382927
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml bupivacaine 0.5% combined with 1500 units hyaluronidase and 1 ml saline per nerve root sleeve (group A)
Trial: 10382927
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml bupivacaine 0.5% combined with 40 mg methylprednisolone solution (group B)
Trial: 10382927
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml bupivacaine 0.5% combined with 1500 units hyaluronidase and 40 mg methylprednisolone solution (group C)
Trial: 8887586
Drug: Natural surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural surfactant treatment
Trial: 6321673
Drug: Preoperative radiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiotherapy and chemotherapy (group R, 76 patients)
Trial: 6321673
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (group C, 88 patients)
Trial: 6321673
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (group C)
Trial: 3948591
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control (preterm)
Trial: 3948591
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control (full-term)
Trial: 18201212
Drug: Liraglutide 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.25 mg/day
Trial: 18201212
Drug: Liraglutide 1.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.9 mg/day
Trial: 16771811
Drug: TAC and
RxNorm normalized name: Nystatin and Triamcinolone Acetonide Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC and steroids
Trial: 10926623
Drug: Oral Salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Salbutamol (12 mg/day for 3 weeks)
Trial: 4046137
Drug: Dietetic-hygienic measures,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietetic-hygienic measures, hypolipidemic agents (mainly probucol and clofibrate), antihypertensive agents (mainly diuretics and beta-blockers)
Trial: 30010438
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg morphine (Group 1)
Trial: 30010438
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg morphine (Group 2)
Trial: 20591813
Drug: Complete anaemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete anaemia correction (haemoglobin target of 13 g/dL using darbepoetin alfa)
Trial: 20591813
Drug: Placebo (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (with a haemoglobin rescue value of 9 g/dL)
Trial: 7618662
Drug: Edrophonium (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium (0.1, 0.3, 0.5, 0.7, 1.0, or 1.5 mg.kg‐1)
Trial: 2694356
Drug: Active infrared
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active infrared laser therapy at 904 nm three times weekly for 2 weeks
Trial: 122428
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg GnRH infusion
Trial: 122428
Drug: 80 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 μg GnRH infusion
Trial: 122428
Drug: 800 μg
RxNorm normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 μg GnRH infusion
Trial: 122428
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg GnRH infusion in boys
Trial: 122428
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy in boys
Trial: 122428
Drug: 800 μg
RxNorm normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 μg GnRH infusion in men
Trial: 30298560
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of ketoprofen lysine salt (KLS)
Trial: 30298560
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of paracetamol/acetaminophen (P)
Trial: 30298560
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ketoprofen lysine salt once a day for the first 3 days of activation
Trial: 27358173
Drug: Atorvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (80 mg + 40 mg before PCI)
Trial: 27358173
Drug: Rosuvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (40 mg twice before PCI)
Trial: 27358173
Drug: Rosuvastatin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (5 mg) and ezetimibe (10 mg) twice before PCI
Trial: 24809262
Drug: Noninvasive ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive ventilation (NIV) immediately after extubation in sequential group
Trial: 22210658
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) 50 mg s.c. once weekly for 36-52 weeks
Trial: 7831635
Drug: Baker Norton
RxNorm normalized name: Bayer Aspirin Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baker Norton metered dose inhaler with Volumatic
Trial: 7831635
Drug: Ventolin metered
RxNorm normalized name: albuterol Metered Dose Inhaler [Ventolin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventolin metered dose inhaler with Volumatic
Trial: 29852092
Drug: RT5 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT5 (5 times weekly)
Trial: 29852092
Drug: RT3 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT3 (3 times weekly)
Trial: 29852092
Drug: RT2 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT2 (2 times weekly)
Trial: 21134243
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sotrastaurin
Trial: 20137762
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg everolimus
Trial: 20137762
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sotrastaurin and everolimus
Trial: 20137762
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sotrastaurin with 2 mg everolimus
Trial: 7589640
Drug: Naltrexone 50
RxNorm normalized name: naltrexone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 50 mg/d orally for 6 months
Trial: 7589640
Drug: Hormonal replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal replacement therapy with E2 patches and medroxyprogesterone acetate
Trial: 90965
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg atenolol daily from admission
Trial: 31760780
Drug: Monitoring changes
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring changes in daily affect
Trial: 31884935
Drug: Fast Dissolving
RxNorm normalized name: Mucinex Sinus-Max Day/Night Fast Dissolving Gels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast Dissolving Tablets (FDT) of Febuxostat
Trial: 27601592
Drug: Adjuvant cyclophosphamide-based
RxNorm normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant cyclophosphamide-based chemotherapy